WO2023047396A1

WO2023047396A1 - Concentrated aqueous cannabinoid compositions

Info

Publication number: WO2023047396A1
Application number: PCT/IL2022/051007
Authority: WO
Inventors: Miron Hazani
Original assignee: Roxx Labs Ltd.
Priority date: 2021-09-22
Filing date: 2022-09-21
Publication date: 2023-03-30

Abstract

The present disclosure generally relates to highly concentrated aqueous compositions comprising a cannabinoid acid salt, processes for the preparation thereof and uses thereof for inhalation.

Description

CONCENTRATED AQUEOUS CANNABINOID COMPOSITIONS

TECHNICAE FIELD

[0001] The present disclosure generally relates to highly concentrated aqueous compositions comprising a cannabinoid acid salt, processes for the preparation thereof and uses thereof for inhalation.

BACKGROUND

[0002] Cannabinoids are a diverse class of chemical compounds that act as ligands to the cannabinoid receptors. The clinical usefulness of the cannabinoids, including A⁹- tetrahydrocannabinol (A⁹-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits, including, but not limited to, anti-spasmodic, antiinflammatory, anti-convulsant, anti-oxidant, neuroprotective, reducing pain, anticancer, and immunomodulatory effects.

[0003] The principle cannabinoids present in herbal cannabis are cannabinoid acids A⁹-tetrahydrocannabinolic acid (A⁹-THCA) and cannabidiolic acid (CBDA) with small amounts of the respective neutral (decarboxylated) cannabinoids - tetrahydrocannabinol and cannabidiol (CBD). In addition, cannabis may contain lower levels of other minor cannabinoids. The relative levels of THCA, CBDA, THC and CBD in the plant material typically depend on the plant species, with specific species being engineered to contain high level of the THC derivatives (THC and THCA).

[0004] Tetrahydrocannabinolic acid (THCA) is a non-psychoactive natural precursor of tetrahydrocannabinol (THC). THCA is found in variable quantities in fresh, undried cannabis, but is progressively decarboxylated to THC with drying, and especially under intense heating such as when cannabis is smoked or cooked into cannabis edibles.

[0005] THC is highly insoluble in water and is typically used in oily compositions. THCA is more soluble in water. However, typical THC compositions are provided as viscous suspensions and/or in organic solvents, such as vegetable glycerin (VG) or propylene glycol (PG). [0006] US 7,524.881 is directed to isolation and purification of THC. It disclosed the extraction of cannabis plant material with heptane, basic extraction of the organic phase with sodium hydroxide at a pH of 12.7-13.2, further extraction of the resultant basic aqueous phase with isopropyl ether, acidification, and treatments with florisil and charcoal to form THC solution, which is then concentrated and purified.

[0007] Hazekamp et al. (Preparative Isolation of Cannabinoids from Cannabis sativa by Centrifugal Partition Chromatography, Journal of Liquid Chromatography & Related Technologies 27(15):2421-2439 • December 2004) discloses a method for the preparative isolation of seven major cannabinoids from Cannabis sativa plant material. Hazekamp discloses the use of a two solvent system, to obtain purified samples of the cannabinoids; (-)-A⁹-(/rans)- tetrahydrocannabinol (A⁹-THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), (-)-A⁹-(trans)-tetrahydrocannabinolic acid-A (THCA), cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA).

[0008] Stepanov I and Naomi F ("Bringing attention to e-cigarette pH as an important element for research and regulation", Tobacco Control 24(4), p. 413-414) discusses pH effects on nicotine in electronic cigarettes.

[0009] US 2014/166028 discloses a method for the administration of nicotine, THC, tobacco, cannabidiol or a base alkaloid. The method includes administering in the oral or nasal cavity an absorption conditioning unit having at least two agents selected from the group consisting of (a) a buffer agent, (b) a capturing agent, (c) a penetration agent, and (d) a thermal agent, to the mammal, and then administering by inhalation a bioactive agent selected from the group consisting of nicotine, THC, cannabidiol and a base alkaloid. The absorption conditioning unit may be in a dosage form not containing a drug. The absorption conditioning unit may create a pH in the oral cavity or nasal cavity of 7.8-10 for a period of ten minutes or more after administration, the dosage form not containing an acid and not containing a drug.

[0010] US 2014/209109 discloses a pharmaceutical composition and administration apparatus including a portable powered vaporizer with a mouthpiece, smokeless vaporizing element, and a removable chamber. The chamber contains a composition comprising tetrahydrocannabinol (THC), cannabidiol (CBD), FCC grade ethanol, flavoring, pharmaceutical grade nicotine, USP grade aqueous glycerin, USP/EP grade propylene glycol, and USP grade vegetable glycerin. [0011] WO 2016/019353 discloses a pharmaceutical formulation of cannabis compounds suitable for pulmonary delivery to a patient, comprising: a volatile liquid, wherein the volatile liquid comprises a mixture of: a cannabis oil extract having a known amount of a medicinal cannabis compound; and an aerosol precursor. The volatile liquid may be in an inhalable form, in an aerosol form and/or in vapor form.

[0012] WO 2020/194297 relates to the field of aerosol generation devices, and to electronic cigarettes configured to generation of aerosols from aqueous formulations of nicotine or cannabis products.

[0013] WO 2021/191891relates to aqueous compositions comprising a cannabinoid acid or a salt thereof, processes for the preparation thereof and uses thereof for inhalation.

[0014] There is an unmet need for improved procedures for the preparation of cannabinoid compositions comprising cannabinoid acids and/or salts thereof.

SUMMARY

[0015] In addition to the exemplary aspects and embodiments described below, further aspects and embodiments will become apparent by reference to the figures and by study of the following detailed descriptions.

[0016] The present invention provides, according to some embodiments, a stable aqueous cannabinoid composition, which is characterized by an exceptionally high load of cannabinoid acid(s), in particular tetrahydrocannabinolic acid (THCA). Specifically, such organic acids tend to have low aqueous solubility, which previously prevented the preparation of stable aqueous formulation. Advantageously, the present composition both maintains its formulation integrity (i.e., the mixture does not break and separate into different phases) and maintains the stability of THCA, which does not undergo rapid decarboxylation to the corresponding cannabinoid (e.g., THC).

[0017] Moreover, the present stable aqueous cannabinoid composition employs a non-ionic surfactant (e.g., polysorbate, such as polysorbate 80), according to some embodiments, which surprisingly enables to achieve remarkably high cannabinoid acid concentration of over 10% w/w, and even 15-20% w/w or more. The person skilled in the art may appreciate the exceptional effect on the aqueous solubility of the organic acid. Specifically, whereas non-ionic surfactants were previously used to enhance solubility, it was unexpected that an aqueous composition having such high cannabinoid acid concentration would result.

[0018] Another unexpected discovery, which contributes to the present invention is that it was found that the basicity of the composition (pH of at least 8.5 or at least 9, at least 10 or between 10 and 12) is suitable for delivery to electronic vaporizer users, although basic aerosols are typically hazardous. This unexpected phenomenon is elaborated and contemplated hereinbelow. Thus, according to some embodiments, the present aqueous composition is basic.

[0019] Another particularly practical advantage of the present aqueous cannabinoid composition is that it is highly viscous, according to some embodiments, and, as a surprising result, can be vaporized with conventional electronic cannabis vaporizers. As elaborated herein, the conventional electronic cannabis vaporizers cannot vaporize known aqueous cannabinoid compositions because of the boiling temperature gap between cannabinoids and water. However, it was surprisingly found that the present composition is suitable for use with vaporizers typically used in the field.

[0020] Thus, according to some embodiments, there is provided a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5. According to some embodiments, there is provided a stable aqueous cannabinoid composition comprising at least 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5.

[0021] According to some embodiments, the stable aqueous cannabinoid composition is in a form selected from the group consisting of: a solution, a suspension, a gel and an emulsion.

[0022] According to some embodiments, the stable aqueous cannabinoid composition is in a form selected from the group consisting of: a gel, a micro-emulsion, nano-emulsion and a colloidal suspension of micro-colloids or nano-colloids.

[0023] According to some embodiments, the stable aqueous cannabinoid composition has an ionic strength in the range of 0.3M to 2M. [0024] According to some embodiments, the stable aqueous cannabinoid composition has a pH in the range of 10 to 12.

[0025] According to some embodiments, the stable aqueous cannabinoid composition comprises at least 15% w/w of the at least one cannabinoid acid or salt thereof.

[0026] According to some embodiments, the non-ionic surfactant comprises a polysorbate. According to some embodiments, the polysorbate is polysorbate 80.

[0027] According to some embodiments, the stable aqueous cannabinoid composition comprises 0.02% w/w to 0.06% w/w polysorbate 80 non-ionic surfactant.

[0028] According to some embodiments, the stable aqueous cannabinoid composition has viscosity in the range of 1.25 to 50 mPa- s at 20°C.

[0029] According to some embodiments, the stable aqueous cannabinoid composition further comprises glycerol.

[0030] According to some embodiments, the at least one cannabinoid acid or salt thereof comprises tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), salts thereof or a combination thereof. According to some embodiments, the at least one cannabinoid acid or salt thereof comprises THCA or a salt thereof.

[0031] According to some embodiments, the stable aqueous cannabinoid composition is substantially devoid of organic solvents.

[0032] According to some embodiments, the stable aqueous cannabinoid composition comprises at least 60% w/w water.

[0033] According to some embodiments, the stable aqueous cannabinoid composition is prepared by a process comprising the steps of:

(a) contacting dry cannabis plant extract with an aqueous base and with the non-ionic surfactant to form an aqueous composition having pH in the range of 10 to 12;

(b) adding a salt or an aqueous salt solution to the composition of step (a) until it reaches an ionic strength of at least 0.7 M, to form phase separation, between a first phase comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, and a second phase;

(c) separating the first phase from the second phase.

[0034] According to some embodiments, the process further comprises extracting a cannabis plant material with a non-aqueous solvent and drying the extract to form the dry cannabis plant extract of step (a).

[0035] According to some embodiments, wherein the aqueous base of step (a) comprises sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate or a combination thereof.

[0036] According to some embodiments, the cannabis plant material comprises a THCA-enriched cannabis strain.

[0037] According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 1 week, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w.

[0038] According to some embodiments, the stable aqueous cannabinoid composition further comprises at least one additive selected from the group consisting of a propellant, an anti-coughing agent and a flavorant.

[0039] According to some embodiments, the stable aqueous cannabinoid composition is formulated for administration via inhalation.

[0040] According to some embodiments, there is provided a process for preparing a stable aqueous cannabinoid composition, comprising the steps of:

(a) contacting dry cannabis plant extract with an aqueous base and a nonionic surfactant to form an aqueous composition having pH in the range of 10 to 14;

(c) separating the first phase from the second phase. [0041] According to some embodiments, the process further comprises extracting a cannabis plant material with a non-aqueous solvent and drying the extract to form the dry cannabis plant extract of step (a). According to some embodiments, the aqueous base of step (a) comprises sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate or a combination thereof. According to some embodiments, the cannabis plant material comprises a THCA-enriched cannabis strain.

[0042] According to some embodiments, there is provided stable aqueous cannabinoid composition, prepared by the process of the present invention.

[0043] According to some embodiments, there is provided a vaporization filling composition comprising the cannabinoid composition as described herein.

[0044] According to some embodiments, the vaporization filling composition is selected from an electronic cigarette cartridge filling composition and a vaporizer cartridge filling composition.

[0045] According to some embodiments, there is provided an electronic vaporizer cartridge comprising a liquid container, wherein the liquid container contains the stable aqueous cannabinoid composition of the present intention.

[0046] According to some embodiments, there is provided a method of delivering a cannabinoid to a user of an electronic vaporizer via inhalation, the method comprising the steps of:

(i) providing the stable aqueous cannabinoid composition of any one of the present invention; and

(ii) aerosolizing the cannabinoid composition of step (a) with an electronic vaporizer, to form an inhalable aerosol, wherein the inhalable aerosol is inhaled by the user of the electronic vaporizer.

[0047] According to some embodiments, the inhalable aerosol formed in step (ii) has a pH in the range of 5.5 to 7.5.

[0048] According to some embodiments, the aerosolizing of step (ii) comprises heating the stable aqueous cannabinoid composition of step (i) with an electronic vaporizer. [0049] According to some embodiments, there is provided an aerosol composition comprising tetrahydrocannabinol (THC) at a total weight of at least 10% w/w based on the total weight of the aerosol composition, and water 60-90% w/w based on the total weight of the aerosol composition, wherein the aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of at most 5 microns.

[0050] According to some embodiments, the aerosol is prepared by aerosolizing the stable aqueous cannabinoid composition of the present invention.

[0051] According to some embodiments, the aerosol has a pH in the range of 5.5 to 7.5.

[0052] According to some embodiments, the aerosol further comprises tetrahydrocannabinolic acid (THC A).

[0053] Certain embodiments of the present disclosure may include some, all, or none of the above advantages. One or more technical advantages may be readily apparent to those skilled in the art from the figures, descriptions and claims included herein. Moreover, while specific advantages have been enumerated above, various embodiments may include all, some or none of the enumerated advantages.

[0054] In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the figures and by study of the following detailed descriptions.

DETAILED DESCRIPTION

[0055] In the following description, various aspects of the disclosure will be described. For the purpose of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the different aspects of the disclosure. However, it will also be apparent to one skilled in the art that the disclosure may be practiced without specific details being presented herein. Furthermore, well- known features may be omitted or simplified in order not to obscure the disclosure.

[0056] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

Liquid cannabinoid compositions

[0057] Provided herein are highly concentrated cannabinoid compositions suitable for the administration of a cannabinoid via inhalation, according to some embodiments. Advantageously, the cannabinoid compositions disclosed herein are provided in an aqueous medium, such as an aqueous suspension, aqueous emulsion, aqueous solution or any mixture thereof. In addition, the THC compositions disclosed herein, when delivered via inhalation, exhibit THC delivery properties similar to cigarettes, thereby providing an efficient substitute for smokers, which is safer and is devoid of smoke or other harmful organic decomposition contaminants. Advantageously, the present composition is highly concentrated and it is viscous compared to known aqueous compositions. Surprisingly, this concentrated and viscous cannabinoid composition is compatible for use using conventional cannabinoid vaporizers, which is in contrast with previously disclosed thinner aqueous compositions, which cannot be vaporized with such vaporizers. According to some embodiments, the cannabinoid composition is aqueous and comprising at least one cannabinoid compound, such as a cannabinoid acid or a salt thereof and a non-ionic surfactant (e.g., polysorbate), which was surprisingly found to enable elevation of the cannabinoid content to more than 10% w/w, as well as elevating the composition viscosity.

[0058] Thus, according to some embodiments, there is provided a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5. According to some embodiments, there is provided a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a surfactant. According to some embodiments, there is provided a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a viscosity enhancing agent.

[0059] According to some embodiments, the aqueous composition has a pH of at least 5. According to some embodiments, the aqueous composition has a pH of at least 6. According to some embodiments, the aqueous composition has a pH of at least 6.5. According to some embodiments, the aqueous composition has a pH of at least 7. According to some embodiments, the aqueous composition has a pH of at least 7.5.

According to some embodiments, the aqueous composition has a pH of at least 8.

According to some embodiments, the aqueous composition has a pH of at least 8.25. According to some embodiments, the aqueous composition has a pH of at least 8.5. According to some embodiments, the aqueous composition has a pH of at least 8.75. According to some embodiments, the aqueous composition has a pH of at least 9. According to some embodiments, the aqueous composition has a pH of at least 9.5. According to some embodiments, the aqueous composition has a pH of at least 10. According to some embodiments, the aqueous composition has a pH of at least 10.5. According to some embodiments, aqueous composition has a pH in the range of 9.5 to 11.5. According to some embodiments, aqueous composition has a pH in the range of 9 to 11. According to some embodiments, aqueous composition has a pH in the range of 10 to 11. According to some embodiments, aqueous composition has a pH in the range of 10.5 to 11.5. According to some embodiments, the stable aqueous cannabinoid composition has a pH in the range of 10 to 12.5. According to some embodiments, the stable aqueous cannabinoid composition has a pH in the range of 9.5 to 12.5. According to some embodiments, the stable aqueous cannabinoid composition has a pH in the range of 10 to 12.

[0060] According to some embodiments, the stable aqueous cannabinoid composition has a pH in the range of 10 to 13, including each value and sub-range within the specified range.

[0061] The term "cannabinoid", as used herein, includes all major and minor cannabinoids found in natural cannabis and hemp material that can be isolated from a natural source or reproduced by synthetic means. This includes delta-9- tetrahydrocannabinol (THC), delta-9-tetrahydrocannabinolic acid and delta-8- tetrahydrocannabinolic acid (THCA), delta-8-Tetrahydrocannabinol, Cannabidiol (CBD), cannabidiolic acid (CBDA), cannabinol (CBN), cannabinolic acid (CBNA), tetrahydrocannabinovarin (THCV), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolic acid (CBGA) and cannabichromene (CBC). The term "cannabinoid" also includes basic salts of the acid mentioned above, for example, THCA-sodium salt and THCA-potassium salt. The term "cannabinoid acid" refers to the carboxylic acid cannabinoid derivatives and to their salts. Non-limiting examples of cannabinoid acids include: delta-9-tetrahydrocannabinolic acid and delta-8-tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), Cannabinolic acid (CBNA), and cannabigerolic acid (CBGA).

[0062] The term "tetrahydrocannabinolic acid" and "THCA acid" are interchangeable and refer to common derivatives of THC, which are substituted in position 2 of the aromatic ring by a carboxylic acid. THC has two dominant isomers,

A⁹-THC and A⁸-THC. Accordingly, THCA has corresponding A⁹ and A⁸ isomers. The chemical structures of the parent tetrahydrocannabinols (A⁹-THC and A⁸-THC) and tetrahydrocannabinolic acids (A⁹-THCA and A⁸-THCA) are presented below:

Delta-9-THCA Delta-8-THCA

[0063] It is to be understood that although the natural THC isomers include an n- C5H11 chain in position 3, derivatives of THC may include other substituents. Therefore, the term tetrahydrocannabinolic acid includes corresponding structures, in which position 3 is substituted by a group, which is either an n-CsHn or a different chemical group.

[0064] The term "tetrahydrocannabinolic acid" should be interpreted broadly referring to all possible stereoconfigurations and salts of the relevant formula. Specifically, the natural THC includes two vicinal asymmetric positions, position 6a and position 10a, as shown above. The two vicinal asymmetric positions exist in trans relative configuration, and both are designated R absolute configuration. Thus, the (6a/?, 10a/?) absolute configuration is the preferred configuration for tetrahydrocannabinolic acids of the current invention, however, said tetrahydrocannabinolic acids are not limited to this configuration According to some embodiments, positions 6a and 10a of the THCA acid are in trans relative configuration. According to some embodiments, position 6a has R absolute configuration. According to some embodiments, position 10a has R absolute configuration. According to some embodiments, the THCA acid has the (6a/?, 10a/?) absolute configuration.

[0065] According to some embodiments, the at least one cannabinoid acid or salt thereof comprises THCA-salt. According to some embodiments, the at least one cannabinoid acid or salt thereof comprises THCA- sodium salt.

[0066] The following figure presents the formulae of THCA salt (or THCA basic salt), THCA metal salt, and particularly, THC sodium salt.

M = cation; THCA salt or THCA basic salt;

M = metal; THCA metal salt;

M = Na; THCA sodium salt

[0067] According to some embodiments, the at least one cannabinoid acid or salt thereof comprises tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), salts thereof or a combination thereof. According to some embodiments, the at least one cannabinoid acid or salt thereof comprises THCA or a salt thereof.

[0068] According to some embodiments, the present stable aqueous cannabinoid composition comprises a surfactant. According to some embodiments, the surfactant in a non-ionic surfactant. According to some embodiments, the present stable aqueous cannabinoid composition comprises a non-ionic surfactant. [0069] The term “surfactant” or surface-active agent as used herein, refers to compounds that lower the surface tension (or interfacial tension) between two liquids, between a liquid and a solid, or between a liquid and a gas. Surfactants may act as detergents, wetting agents, emulsifiers, foaming agents, or dispersants. Surfactants are usually organic compounds that are at least partially amphiphilic, i.e., typically containing a hydrophobic tail group and hydrophilic polar head group. These properties typically allow solubility of the surfactant in organic solvents as well as in water, and allow the surfactant to promote solubilization or at least dispersal of fatty/waxy materials in water.

[0070] The term “non-ionic surfactant” as used herein refers to any substance, in particular a detergent, that can adsorb at surfaces and interfaces, like liquid to air, liquid to liquid, liquid to container or liquid to any solid and which has no charged groups in its hydrophilic group(s) (sometimes referred to as “heads”). The non-ionic surfactant of the present invention may be selected, according to some embodiments, from the group of: detergents such as ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides and sorbitan fatty acid esters, polysorbate such as polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-80, super refined polysorbate 20, super refined polysorbate 40, super refined polysorbate 60 and super refined polysorbate 80 (where the term “super refined” is used by the supplier Croda for their high purity Tween products), poloxamers such as poloxamer 188 and poloxamer 407, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives such as alkylated and alkoxylated derivatives (Tweens, e.g. Tween-20 or Tween-80), block copolymers such as polyethyleneoxide/polypropyleneoxide block copolymers (e.g. Pluronics/Tetronics, Triton X-100 and/or Synperonic PE/L 44 PEL) and ethoxylated sorbitan alkanoates surfactants (e.g. Tween20, Tween-40, Tween-80, Brij-35), diglycerol laurate, diglycerol caprate, diglycerol caprylate, diglycerol monocaprylate, polyglycerol laurate, polyglycerol caprate and polyglycerol caprylate.

[0071] Examples of other non-ionic surfactants include, but are not limited to:

[0072] 1. Reaction products of a natural or hydrogenated castor oil and ethylene oxide. The natural or hydrogenated castor oil may be reacted with ethylene oxide in a molar ratio of from about 1:35 to about 1:60, with optional removal of the PEG component from the products. Various such surfactants are commercially available, e.g., the CREMOPHOR series from BASF Corp. (Mt. Olive, N.J.), such as CREMOPHOR RH 40 which is PEG40 hydrogenated castor oil which has a saponification value of about 50- to 60, an acid value less than about one, a water content, i.e., Fischer, less than about 2%, an no ⁶⁰ of about 1.453-1.457, and an HLB of about 14-16;

[0073] 2. Polyoxyethylene fatty acid esters that include polyoxyethylene stearic acid esters, such as the MYRJ series from Uniqema e.g., MYRJ 53 having a m.p. of about 47° C. Particular compounds in the MYRJ series are, e.g., MYRJ 53 having an m.p. of about 47° C. and PEG-40-stearate available as MYRJ 52;

[0074] 3. Sorbitan derivatives that include the TWEEN series from Uniqema, e.g.,

TWEEN 60;

[0075] 4. Polyoxyethylene-polyoxypropylene co-polymers and block co-polymers or poloxamers, e.g., Pluronic F127 or Pluronic F68 from BASF or Synperonic PE/L from Croda;

[0076] 5. Polyoxyethylene alkyl ethers, e.g., such as polyoxyethylene glycol ethers of C12-C18 alcohols, e.g., polyoxyl 10- or 20-cetyl ether or polyoxyl 23-lauryl ether, or 20-oleyl ether, or polyoxyl 10-, 20- or 100-stearyl ether, as known and commercially available as the BRU series from Uniqema. Particularly useful products from the BRU series are BRU 58; BRU 76; BRU 78; BRU 35, i.e. polyoxyl 23 lauryl ether; and BRU 98, i.e., polyoxyl 20 oleyl ether. These products have a m.p. between about 32°C to about 43° C.;

[0077] 6. Water-soluble tocopheryl PEG succinic acid esters available from

Eastman Chemical Co. with a m.p. of about 36° C., e.g., TPGS, e.g., vitamin E TPGS.

[0078] 7. PEG sterol ethers having, e.g., from 5-35 [CH2 — CH, — O] units, e.g., 20-

30 units, e.g., SOLULAN C24 (Choleth-24 and Cetheth-24) from Chemron (Paso Robles, Calif.); similar products which may also be used are those which are known and commercially available as NIKKOL BPS-30 (polyethoxylated 30 phytosterol) and NIKKOL BPSH-25 (polyethoxylated 25 phytostanol) from Nikko Chemicals;

[0079] 8. Polyglycerol fatty acid esters, e.g., having a range of glycerol units from

4-10, or 4, 6 or 10 glycerol units. For example, particularly suitable are deca-/hexa- /tetraglyceryl monostearate, e.g., DECAGLYN, HEXAGLYN and TETRAGLYN from

Nikko Chemicals;

[0080] 9. Alkylene polyol ether or ester, e.g., lauroyl macrogol-32 glycerides and/or stearoyl macrogol-32 glycerides which are GELUCIRE 44/14 and GELUCIRE 50/13 respectively;

[0081] 10. Polyoxyethylene mono esters of a saturated Cioto C22, such as

Cis substituted e.g. hydroxy fatty acid; e.g. 12 hydroxy stearic acid PEG ester, e.g. of PEG about e.g. 600-900 e.g. 660 Daltons MW, e.g. SOLUTOL HS 15 from BASF (Ludwigshafen, 20 Germany). According to a BASF technical leaflet MEF 15 IE (1986), SOLUTOL HS 15 comprises about 70% polyethoxylated 12-hydroxystearate by weight and about 30% by weight unesterified polyethylene glycol component. It has a hydrogenation value of 90 to 110, a saponification value of 53 to 63, an acid number of maximum 1, and a maximum water content of 0.5% by weight;

[0082] 11. Polyoxyethylene-polyoxypropylene-alkyl ethers, e.g. polyoxyethylene- polyoxypropylene-ethers of Cnto Cis alcohols, e.g. polyoxyethylen-20- polyoxypropylene-4-cetylether which is commercially available as NIKKOL PBC 34 from Nikko Chemicals;

[0083] 12. Polyethoxylated distearates, e.g. commercially available under the tradenames ATLAS G 1821 from Uniqema and NIKKGCDS-6000P from Nikko Chemicals.

[0084] According to some embodiments, the non-ionic surfactant comprises a polysorbate.

[0085] The term “polysorbate” as used herein refers to oleate esters of sorbitol and its anhydrides, typically copolymerized with ethylene oxide. According to some embodiments, the polysorbate has a molecular weight ranging from about 1200 Da (approximate molecular weight of polysorbate 20) to about 1350 Da (approximate molecular weight of polysorbate 80). Polysorbates may be generally represented by the following structure:

[0086] wherein w+x+y+z ranges from about 10 to about 120, and in particular embodiments, from about 10 to about 30, and wherein R is a Ce-Cis fatty acid radical. Exemplary polysorbates within the scope of the present definition include, but are not limited to, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, and polysorbate 80. The polysorbate number is determined by the number of its repeating (CH2CH2O) moieties. For example, for polysorbate 20:

[0087] According to some embodiments, the polysorbate is selected from the group consisting of: polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80 and polysorbate 100. Each possibility represents a separate embodiment of the invention. According to some embodiments, the polysorbate is polysorbate 80.

[0088] According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.01% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.02% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.03% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.03% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.04% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.05% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.06% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.07% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.08% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.01% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.02% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.03% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.03% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.04% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.05% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.06% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.07% the non-ionic surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 0.08% the non-ionic surfactant w/w.

[0089] According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 5% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 4% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 3% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 2% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 1% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 0.75% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 0.5% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 0.33% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 0.25% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 0.2% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 0.15% surfactant w/w. According to some embodiments, the stable aqueous cannabinoid composition comprises no more than 0.1% surfactant w/w.

[0090] According to some embodiments, the stable aqueous cannabinoid composition comprises 0.01% w/w to 0.1% of the non-ionic surfactant w/w (based on the weight of the total aqueous cannabinoid composition). According to some embodiments, the stable aqueous cannabinoid composition comprises 0.02% w/w to 0.06% of the non-ionic surfactant w/w.

[0091] According to some embodiments, the stable aqueous cannabinoid composition comprises 0.02% w/w to 0.06% w/w polysorbate 80 non-ionic surfactant. According to some embodiments, the stable aqueous cannabinoid composition comprises 0.01% w/w to 0.1% w/w polysorbate 80 non-ionic surfactant.

[0092] Surfactants, including non-ionic surfactants are known to improve the solubility of some compounds under some circumstances or to bring compounds into a stable emulsion or suspension. However, the immense effect that the present non-ionic surfactant has on the compositional properties is unexpected. Specifically, cannabinoid acids, such as THCA and CBDA have very low aqueous solubility (about 0.2% w/w), where above this range, the cannabinoids separate from the water to form a separate phase. In contrast, the present aqueous cannabinoid composition comprises over 10% THCA w/w content (as basic salt), and as exemplified above can reach about 17% THCA w/w content. Such an observation is highly unexpected and beneficial, for many cannabis users. Specifically, high concentrations are required to get an immediate and effective physiological response such as pain relief or anxiety relief.

[0093] Moreover, in contrast with many water-insoluble organic material, which are suspended, gelled or emulsified in aqueous media, the present composition was found to be highly stable as elaborated below (e.g., the suspension/emulsion/gel does not break into phases after time, and the cannabinoid acids do not decarboxylate). [0094] Another surprise which was observed, is that the present aqueous cannabinoid acid-surfactant composition is compatible with conventional electronic vaporizing devices, which unexpectedly enable the vaporization of the aqueous composition, such that the water is aerosolized substantially in parallel to the cannabinoids.

[0095] As detailed herein, according to some embodiments, the present stable aqueous cannabinoid composition comprises more than 10% w/w of at least one cannabinoid acid or a salt thereof.

[0096] As used herein, when relating to cannabinoid percentages in liquid compositions, unless specified otherwise, the volume ratio, or w/w % is referred. For example, the phrase "the percentage of the at least one cannabinoid acid or a salt thereof is within the range of 12 to 18%" refers to a liquid formulation, in which a single weight unit of the formulation includes from 0.12 to 0.18 the weight unit of cannabinoid acid or a salt thereof.

[0097] It is noted that when cannabinoid acid salts are referred, the calculated mass does not include the mass of the counter cation. Thus, a composition, which totally weighs 100 grams and includes 40 millimoles (mmols) of THCA-sodium salt (380.47 gr/mol) is said to include 14.3 grams of THCA, based on the molecular weight of THCA anion (357.48 gr/mol), which translates to 14.3% THCA w/w, according to the present definition. This, while the w/w of the cannabinoid including the cation will be higher (380.47 gr/mol x 40 mmol = 15.2 gr). This way of calculation prevents inconsistencies and discrepancies of measurements with compositions, which include heavy cations. This way of calculation also emphasizes the great improvement of the present aqueous cannabinoid acid-surfactant composition, which is highly concentrated.

[0098] According to some embodiments, the stable aqueous cannabinoid composition comprises at least 11% w/w of the of at least one cannabinoid acid or salt thereof. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 12% w/w of the of at least one cannabinoid acid or salt thereof. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 13% w/w of the of at least one cannabinoid acid or salt thereof. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 14% w/w of the of at least one cannabinoid acid or salt thereof. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 15% w/w of the of at least one cannabinoid acid or salt thereof. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 16% w/w of the of at least one cannabinoid acid or salt thereof.

[0099] According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 10.1% to 30% w/w, including each value and sub-range within the specified range. According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 10.1% to 25% w/w. According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 10.1% to 20% w/w. According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 11% to 19% w/w. According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 12% to 18% w/w.

[00100] According to some embodiments, the concentration of the at least one cannabinoid acid or a salt thereof in the cannabinoid composition is within the range of 100 to 300 mg/ml, including each value and sub-range within the specified range. According to some embodiments, the concentration of the at least one cannabinoid acid or a salt thereof in the cannabinoid composition is within the range of 100 to 250 mg/ml. According to some embodiments, the concentration of the at least one cannabinoid acid or a salt thereof in the cannabinoid composition is within the range of 100 to 200 mg/ml.

[00101] According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 29 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 30 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 32 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 34 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 36 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 38 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 40 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 42 millimolar (mM). According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is at least 44 millimolar (mM).

[00102] According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 25 to 80 mM. According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 30 to 60 mM. According to some embodiments, the concentration of the at least one cannabinoid acid or salt thereof in the stable aqueous cannabinoid composition is in the range of 35 to 55 mM.

[00103] Advantageously, in addition to the surprising effects disclosed above, it was surprisingly found that the present composition is highly viscous. This property enables better hold of the composition in electronic vaporized containers and cartridges, as thin aqueous compositions tend to spill and required specialized containers and cartridges.

[00104] According to some embodiments, the stable aqueous cannabinoid composition has viscosity in the range of 1.25 to 50 mPa- s at 20°C.

[00105] As used herein the terms "formulation" and "compositions" generally refer to any mixture, solution, emulsion, dispersion, suspension or the like that contains an active ingredient, such as cannabinoid, and, optionally, a carrier. The carrier may be any carrier acceptable for smoking, that is compatible for delivery with the active agent, such as water and surfactant(s).

[00106] According to some embodiments, the stable aqueous cannabinoid composition is in a form selected from the group consisting of: a solution, a suspension, a gel and an emulsion. [00107] The term "gel" as used herein broadly refers a semi-solid that can have properties ranging from soft and weak to hard and tough. Gels are defined as a substantially dilute cross-linked system, which exhibits no flow when in the steadystate, although the liquid phase may still diffuse through this system. A gel has been defined phenomenologically as a soft, solid or solid-like material consisting of two or more components, one of which is a liquid, present in substantial quantity. By weight, gels are mostly liquid, yet they behave like solids because of a three-dimensional crosslinked network within the liquid. It is the crosslinking within the fluid that gives a gel its structure (hardness) and contributes to the adhesive stick (tack). In this way, gels are a dispersion of molecules of a liquid within a solid medium.

[00108] The term "emulsion" as used herein broadly refers to a mixture of two or more liquids that are normally substantially not miscible (unmixable or unblendable) owing to liquid-liquid phase separation. Emulsions are part of a more general class of two-phase systems of matter called colloids. In an emulsion, one liquid (the dispersed phase) is dispersed in the other (the continuous phase). Emulsions tend to have a cloudy appearance because the many phase interfaces scatter light as it passes through the emulsion. Emulsions, being liquids, do not exhibit a static internal structure. The droplets dispersed in the continuous phase (sometimes referred to as the "dispersion medium") are usually assumed to be statistically distributed to produce roughly spherical droplets.

[00109] The term "suspension " as used herein refers to a heterogeneous mixture of a fluid that contains solid particles sufficiently large for sedimentation. The particles may be visible to the naked eye, usually must be larger than one micrometer, and will eventually settle, although the mixture is only classified as a suspension when and while the particles have not settled out. A suspension is a heterogeneous mixture in which the solute particles do not dissolve, but get suspended throughout the bulk of the solvent, left floating around freely in the medium. The internal phase (solid) is dispersed throughout the external phase (fluid) through mechanical agitation, with the use of certain excipients or suspending agents.

[00110] The term "solution" as used herein broadly refers to a combination, mixture and/or admixture of ingredients having at least one liquid component. Thus, the term "aqueous solution" refers to any solution, in which at least one of its liquid components is water, wherein at least 50% of its weight is water. Aqueous solutions typically include water in greater quantity or volume than a solute. Typical additional solvents include alcohols, aldehydes, ketones, sulfoxides, sulfones, nitriles and/or any other suitable solubilizing molecule or carrier compound. Preferably, "solution" refers broadly to a mixture of miscible substances, where one substance dissolves in a second substance. More preferably, in a solution the essential components are homogeneously mixed and that the components are subdivided to such an extent that there is no appearance of light scattering visible to the naked eye when a one inch diameter bottle of the mixture is viewed in sunlight.

[00111] According to some embodiments, the stable aqueous cannabinoid composition is in a form selected from the group consisting of: a suspension, a gel, an emulsion and mixtures thereof. Each possibility represents a separate embodiment of the invention.

[00112] As detailed above, suspensions, gels and emulsions differ in their physical properties. However, some compositions may be characterized as gel-suspension mixture, gel-emulsion mixture, emulsion-suspension mixture, and the like. For example, the main difference between emulsions and suspensions is the state of the dispersed phase, which is solid in suspension and liquid in emulsions. Thus, a liquid composition, which includes both solids and liquid as dispersed phase, is referred herein as emulsion-suspension mixture, where the same logic similarly applies to the other optional mixtures disclosed herein.

[00113] According to some embodiments, the stable aqueous cannabinoid composition is in a form selected from the group consisting of: a suspension, a gel and an emulsion. According to some embodiments, the stable aqueous cannabinoid composition is a suspension or a gel. According to some embodiments, the stable aqueous cannabinoid composition is a suspension or an emulsion. According to some embodiments, the stable aqueous cannabinoid composition is a gel or an emulsion.

[00114] According to some embodiments, the stable aqueous cannabinoid composition comprises a gel. According to some embodiments, the stable aqueous cannabinoid composition is a gel. [00115] According to some embodiments, the stable aqueous cannabinoid composition comprises a gelling agent. According to some embodiments, the stable aqueous cannabinoid composition is a hydrogel.

[00116] According to some embodiments, the stable aqueous cannabinoid composition is in a form selected from the group consisting of: a gel, a micro-emulsion, nano-emulsion and a colloidal suspension of micro-colloids or nano-colloids.

[00117] According to some embodiments, the stable aqueous cannabinoid composition comprises an emulsion. According to some embodiments, the stable aqueous cannabinoid composition is an emulsion.

[00118] According to some embodiments, the emulsion is a nano-emulsion or a micro-emulsion. According to some embodiments, the emulsion is a nano-emulsion. According to some embodiments, the emulsion is a micro-emulsion.

[00119] According to some embodiments, the stable aqueous cannabinoid composition comprises a suspension. According to some embodiments, the stable aqueous cannabinoid composition is a suspension.

[00120] According to some embodiments, the suspension is a nano- suspension or a micro-suspension. According to some embodiments, the suspension is a nanosuspension. According to some embodiments, the suspension is a micro-suspension.

[00121] According to some embodiments, the suspension or emulsion comprises micelles.

[00122] According to some embodiments, the cannabinoid composition is consisting of the aqueous solution, gel, suspension or emulsion.

[00123] It was surprisingly found that the high cannabinoid acid content of the present composition may be achieved even in the substantial absence of any organic solvents.

[00124] According to some embodiments, the stable aqueous cannabinoid composition is substantially devoid of organic solvents.

[00125] According to some embodiments, the stable aqueous cannabinoid composition is substantially devoid of organic solvents. [00126] As used herein, “substantially devoid” means that a preparation or composition according to the invention that generally contains less than 3% of the stated substance, such as less than 1% or less than 0.5%.

[00127] According to some embodiments, the stable aqueous cannabinoid composition comprises less than 10% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 8% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 6% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 5% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 4% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 3% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 2% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 1% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition less comprises than 0.5% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 0.4% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 0.3% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 0.2% w/w organic solvents. According to some embodiments, the stable aqueous cannabinoid composition comprises less than 0.1% w/w organic solvents.

[00128] According to some embodiments, the organic solvent is selected from the group consisting of: dichloromethane, chloroform. Benzene, toluene, chlorobenzene, hexane, pentane, hexanes, heptane, dimethylformamide, dimethyl sulfoxide, acetone, methanol and combinations thereof. Each possibility represents a separate embodiment of the invention.

[00129] The heated liquid in conventional electronic vaporizers (e-cigarettes, vaping devices and the like) usually includes a composition or mixture of cannabinoids with humectants, having relatively low latent heat of vaporization, such as propylene glycol (PG) or vegetable glycerin (VG). Said composition is typically referred to as “e-juice”. The liquid mixture is typically drawn into a wicking material that is in contact with a heating element, which may consist a coil of a conducting material to be heated when electric current is driven there through. When not contacted with a liquid, or after the liquid is substantially evaporated the temperature of the coil can reach in some instances a temperature of over 800°C. It is to be understood that in contrast with known electronic vaporizer compositions, which employ THC formulations comprising PG and/or VG, which are hazardous upon heating and decomposition, the present invention provides aqueous cannabinoid formulations and do not require hazardous organic solvents.

[00130] According to some embodiments, the stable aqueous cannabinoid composition is in liquid form. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 35% w/w water. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 40% w/w water. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 45% w/w water. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 50% w/w water. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 55% w/w water. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 60% w/w water. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 75% w/w water. According to some embodiments, the stable aqueous cannabinoid composition comprises at least 70% w/w water. It is to be understood that the phrase "stable aqueous cannabinoid composition comprises at least 60% w/w water" means that each gram of the total composition includes at least 600 milligrams of water and at most 400 milligrams of materials other than water.

[00131] According to some embodiments, the present composition includes cannabinoid acid salts (e.g., sodium tetrahydrocannabinolate) and other salts, such as basic salts that are employed in the cannabinoid acid neutralization (e.g., sodium hydroxide). It is hypothesized that above a certain total salt concentration, or ionic strength, the present composition breaks from a continuous dispersion to phase separation or precipitation. [00132] According to some embodiments, the stable aqueous cannabinoid composition has an ionic strength in the range of 0.3M to 2M. According to some embodiments, the stable aqueous cannabinoid composition has an ionic strength in the range of 0.3M to 1.75M. According to some embodiments, the stable aqueous cannabinoid composition has an ionic strength in the range of 0.3M to 1.5M. According to some embodiments, the stable aqueous cannabinoid composition has an ionic strength in the range of 0.3M to 1.25M. According to some embodiments, the stable aqueous cannabinoid composition has an ionic strength in the range of 0.3M to IM.

[00133] As detailed herein the present aqueous cannabinoid composition is a stable composition.

[00134] As used herein, the term “stable composition”, refers to a stable suspension, stable emulsion, stable gel, and the like, and means that the composition shows no visible stratification, phase separation or settling for a period of at least about 6 hours, at least about 12 hours or at least about 24 hours under stationary condition at room temperature. A “stable cannabinoid composition”, as used herein further relates to such a stable composition, which is also characterized in the chemical stability of the cannabinoid(s) contained therein. In particular, it is known that cannabinoid acids, such as THCA are thermally unstable and decompose rapidly upon heating (e.g., when present in a vaporizer cartridge, in the vicinity of the heating unit thereof) and slowly at room temperature. However, deprotonated THCA was found to be thermally stable and as a result, the present composition, when held at high pH, is chemically stable

[00135] According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 1 day, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 2 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 3 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 4 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 5 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 6 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 1 week, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 10 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 2 weeks, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 3 weeks, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 30 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w.

[00136] According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 1 day, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 2 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 3 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 4 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 5 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 6 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 1 week, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 10 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 2 weeks, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 3 weeks, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w. According to some embodiments, the stable aqueous cannabinoid composition is stable for at least 30 days, during which concentration of the least one cannabinoid acid or a salt thereof remains above 15% w/w.

[00137] According to some embodiments, the stable aqueous cannabinoid composition further comprises at least one carrier acceptable for inhalation. According to some embodiments, the carrier is stable under basic pH conditions. According to some embodiments, the carrier is water soluble under basic pH conditions. According to some embodiments, the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier, which is acceptable for inhalation. According to some embodiments, the pharmaceutically acceptable carrier is stable under basic pH conditions. According to some embodiments, the pharmaceutically acceptable carrier is water soluble under basic pH conditions.

[00138] According to some embodiments, the stable aqueous cannabinoid composition further comprises glycerol. According to some embodiments, the carrier acceptable for inhalation comprises glycerol. According to some embodiments, the carrier acceptable for inhalation is glycerol. According to some embodiments, the viscosity enhancing agent comprises glycerol. According to some embodiments, the viscosity enhancing agent is glycerol. According to some embodiments, the glycerol is present in the stable aqueous cannabinoid composition at a concentration of 0.5-10% w/w, 1-10% w/w, 2-10% w/w, 3-10% w/w, 4-10% w/w, or 5-10% w/w, based on the total weight of the stable aqueous cannabinoid composition. Each possibility represents a separate embodiment of the invention. [00139] According to some embodiments, the stable aqueous cannabinoid composition further comprises at least one stabilizer. According to some embodiments, the stabilizer is stable under basic pH conditions. According to some embodiments, the stabilizer is water soluble under basic pH conditions.

[00140] According to some embodiments, the cannabinoid composition further comprises at least one additive selected from the group consisting of a propellant, an anti-coughing agent and a flavorant. According to some embodiments, the cannabinoid composition further comprises at least one additive selected from the group consisting of an anti-coughing agent and a flavorant. According to some embodiments, the cannabinoid composition further comprises at least one anti-coughing agent. According to some embodiments, the cannabinoid composition further comprises at least one flavorant.

[00141] According to some embodiments, the cannabinoid composition further comprises at least one additive at a concentration of 0.1-1% w/w. According to some embodiments, the cannabinoid composition further comprises at least one additive at a concentration of 0.1-0.5% w/w. According to some embodiments, the cannabinoid composition further comprises at least one additive at a concentration of 0.1-0.3% w/w.

[00142] According to some embodiments, the additive is approved for use in inhaling compositions. According to some embodiments, the additive is stable at basic aqueous conditions. According to some embodiments, the additive is soluble at basic aqueous conditions.

[00143] According to some embodiments, the flavorant is a sweetener. According to some embodiments, the sweetener is selected from the group of artificial sweeteners including saccharine, aspartame, dextrose and fructose.

[00144] According to some embodiments, the additive is selected from menthol, eucalyptol, tyloxapol and a combination thereof. According to some embodiments, the additive is selected from menthol, eucalyptol, tyloxapol and a combination thereof, and is present at a concentration of 0.1-0.5% w/w based on the total weight of the cannabinoid composition.

[00145] According to some embodiments, the cannabinoid composition further comprises at least one preservative. According to some embodiments, the preservative is selected from the group consisting of benzyl alcohol, propylparaben, methylparaben, benzalkonium chloride, phenylethyl alcohol, chlorobutanol, potassium sorbate, phenol, m-cresol, o-cresol, p- cresol, chlorocresol and combinations thereof.

[00146] The term "anti-coughing agent" as used herein refers to an active agent used for the suppression, alleviation or prevention of coughing and irritations and other inconveniencies in the large breathing passages that can, or may, generate coughing. Anti-coughing agent include, but are not limited to antitussives, which suppress coughing, and expectorants, which alleviate coughing, while enhancing the production of mucus and phlegm. Anti-coughing agents may ease the administration of inhaled aerosols.

[00147] According to some embodiments, the at least one anti-coughing agent is selected from expectorants, antitussives or both. According to some embodiments, the at least one anti-coughing agent is selected from the group consisting of menthol, dextromethorphan, dextromethorphan hydrobromide, hydrocodone, caramiphen dextrorphan, 3 -methoxy morphinan or morphinan- 3-ol, carbetapentane, codeine, acetylcysteine and combinations thereof.

Preparation of liquid cannabinoid compositions

[00148] According to some embodiments, the stable aqueous cannabinoid composition is prepared by a process comprising the steps of:

(a) contacting dry cannabis plant extract with an aqueous base and with the non-ionic surfactant to form an aqueous composition having pH in the range of 9.5 to 14;

(b) adding a salt or an aqueous salt solution to the composition of step (a) until it reaches an ionic strength of at least 0.6M, to form phase separation, between a first phase comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, and a second phase;

(c) separating the first phase from the second phase.

[00149] According to some embodiments, there is provided a process for preparing a stable aqueous cannabinoid composition, comprising the steps of: (a) contacting dry cannabis plant extract with an aqueous base and a nonionic surfactant to form an aqueous composition having pH in the range of 10 to 14;

(c) separating the first phase from the second phase.

[00150] According to some embodiments, step (a) comprises contacting the dry cannabis plant extract with an aqueous base and with the non-ionic surfactant to form an aqueous composition having pH in the range of 9.5 to 14. According to some embodiments, step (a) comprises contacting the dry cannabis plant extract with an aqueous base and with the non-ionic surfactant to form an aqueous composition having pH in the range of 9.5 to 13.5. According to some embodiments, step (a) comprises contacting the dry cannabis plant extract with an aqueous base and with the non-ionic surfactant to form an aqueous composition having pH in the range of 9.75 to 13. According to some embodiments, step (a) comprises contacting the dry cannabis plant extract with an aqueous base and with the non-ionic surfactant to form an aqueous composition having pH in the range of 10 to 12.5. According to some embodiments, step (a) comprises contacting the dry cannabis plant extract with an aqueous base and with the non-ionic surfactant to form an aqueous composition having pH in the range of 10 to 12.

[00151] Step (a) of the present process involves contacting dry cannabis plant extract with an aqueous base. The term aqueous base refers to any solution, emulsion or suspension comprising at least 50% water and having a pH above 10.

[00152] According to some embodiments, the cannabis plant extract is selected from the group consisting of: crude cannabis extract, a cannabis distillate, a cannabis isolate, a winterized cannabis extract, cannabis rosin, cannabis resin, cannabis wax, cannabis shatter or a combination thereof. According to some embodiments, the dry cannabis plant extract comprises a cannabis concentrate. According to some embodiments, the dry cannabis plant extract comprises a cannabis rosin. According to some embodiments, the dry cannabis plant extract comprises an ethanol extract.

[00153] According to some embodiments, step (b) comprises adding a salt or an aqueous salt solution to the composition of step (a) until it reaches an ionic strength of at least 0.6M. It is to be understood that the salt, which is used to elevate the ionic strength and promote phase separation, may be any organic or inorganic neutral or acidic ionic compound, according to some embodiments. Specifically, according to some embodiments, the salt may be the same base (e.g., sodium hydroxide, potassium hydroxide and the like) which is used to basify the mixture in step (a). In such cases, steps (a) and (b) may be either individual sequential steps or a continuous step.

[00154] According to some embodiments, step (b) comprises adding a salt or an aqueous salt solution to the composition of step (a) until it reaches an ionic strength of at least 0.6M. According to some embodiments, step (b) comprises adding a salt or an aqueous salt solution to the composition of step (a) until it reaches an ionic strength of at least 0.7 M. According to some embodiments, step (b) comprises adding a salt or an aqueous salt solution to the composition of step (a) until it reaches an ionic strength of at least 0.8 M.

[00155] As detailed herein, according to some embodiments, the salt addition of step (b) results in the phase separation, between a first phase and a second phase. As a result of the phase separation, two separate phases surprisingly form. A first phase has an exceptionally high THCA concentration (e.g., above 10% THCA w/w) and a second phase has much lower THCA concentration (e.g., between 1% to 7% THCA w/w). This surprising phenomenon enable to isolate the first, highly concentrated phase, for use for inhalation.

[00156] According to some embodiments, the first phase has higher density than the second phase. As a result, the bottom phase may be used for the preparation of the present stable aqueous cannabinoid composition.

[00157] According to some embodiments, the first phase is aqueous and comprises more than 10% w/w, more than 11% w/w, more than 12% w/w, more than 13% w/w, more than 14% w/w, or more than 15% w/w of at least one cannabinoid acid or a salt thereof. Each possibility represents a separate embodiment of the invention. [00158] According to some embodiments, the second phase is aqueous and comprises less than 10% w/w, less than 9% w/w, less than 8% w/w, less than 7% w/w, less than 6% w/w, or less than 5% w/w of at least one cannabinoid acid or a salt thereof. Each possibility represents a separate embodiment of the invention.

[00159] According to some embodiments, the first phase has ionic strength in the range of 0.3 to 2M.

[00160] According to some embodiments, the first phase has viscosity in the range of 1.25 to 50 mPa- s at 20°C. According to some embodiments, the second phase has viscosity below 1.25 mPa- s at 20°C.

[00161] According to some embodiments, step (c) comprises separating the first phase from the second phase and discarding the second phase.

[00162] According to some embodiments, the process further comprises extracting a cannabis plant material with a non-aqueous solvent and drying the extract to form the dry cannabis plant extract of step (a).

[00163] According to some embodiments, the non-aqueous solvent of step (a) is a non-toxic solvent. According to some embodiments, the non-aqueous solvent of step (a) is a non-toxic solvent.

[00164] Specifically, the product of the present process is to be used for inhalation by a human subject, according to some embodiments, and it is thus preferable that the solvent is non-toxic to ensure that residues thereof in the resulting composition will not harm the health of the subject. According to some embodiments, the non-aqueous solvent of step (a) is not methanol. According to some embodiments, the non-aqueous solvent of step (a) is devoid of methanol.

[00165] According to some embodiments, the non-aqueous solvent of step (a) is a single species solvent. According to some embodiments, the non-aqueous solvent of step (a) comprises a mixture of solvents.

[00166] According to some embodiments, the non-aqueous solvent is an organic solvent.

[00167] As used herein the term "organic solvent" refers to an organic molecule capable of at least partially dissolving another substance (i.e., the solute). Organic solvents may be liquids at room temperature, according to some embodiments. In some embodiments, the organic solvent may be formed by the combination of two or more organic solvents.

[00168] According to some embodiments, the organic solvent is an alcohol, an ether, an ester, an amide, an aldehyde, a sulfoxide, a sulfone, an aromatic hydrocarbon, a halogenated aromatic cycle, an alkane, a haloalkane, a ketone, a nitrile, and combinations thereof.

[00169] According to some embodiments, the organic solvent is selected from the group consisting of: ethanol, n-propanol, isopropanol, 1 -butanol, 2-butanol, secbutanol, t-butanol, 1 -pentanol, 2-pentanol, 3 -pentanol, neopentanol, 3 -methyl- 1- butanol, 2-methyl-l -butanol, 3-methyl-2 -butanol, 2-methyl-2-butanol, ethylene glycol, ethylene glycol monomethyl ether, diethyl ether, methyl ethyl ether, ethyl propyl ether, methyl propyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, acetone, ethyl methyl ketone, diethyl ketone, dimethyl sulfoxide, dimethyl sulfone, sulfolane, dimethyl formamide, dimethyl acetamide, acetamide, N-methylpyrrolidone, acetonitrile, propionitrile, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methyl formate, ethyl formate, ethyl propionate, methyl propionate, chloroform, dichloromethane, tetrachloroethylene, chlorobenzene, toluene, benzene, xylene, hexane, hexanes, petroleum ether, pentane, pentanes, heptane, octane, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane and combinations thereof. Each possibility represents a separate embodiment of the present invention. According to some embodiments, the organic solvent is selected from the group consisting of: ethanol, n-propanol, isopropanol, 1- butanol, 2-butanol, sec -butanol, t-butanol, 1 -pentanol, 2-pentanol, 3 -pentanol, neopentanol, 3 -methyl- 1 -butanol, 2-methyl-l -butanol, 3-methyl-2-butanol, 2-methyl- 2 -butanol, ethylene glycol, ethylene glycol monomethyl ether, diethyl ether, methyl ethyl ether, ethyl propyl ether, methyl propyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, acetone, ethyl methyl ketone, diethyl ketone, tetrachloroethylene, dimethyl sulfoxide, dimethyl sulfone, sulfolane, dimethyl formamide, dimethyl acetamide, acetamide, N- methylpyrrolidone, acetonitrile, propionitrile, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methyl formate, ethyl formate, ethyl propionate, methyl propionate, chloroform, dichloromethane, chlorobenzene, toluene, benzene, xylene and combinations thereof. Each possibility represents a separate embodiment of the present invention.

[00170] According to some embodiments, the organic solvent comprises an alcohol selected from the group consisting of: ethanol, n-propanol, isopropanol, 1 -butanol, 2- butanol, sec -butanol, t-butanol, 1 -pentanol, 2-pentanol, 3 -pentanol, neopentanol, 3- methyl-1 -butanol, 2-methyl-l -butanol, 3-methyl-2-butanol, 2-methyl-2-butanol, ethylene glycol, ethylene glycol monomethyl ether and a combination thereof.

[00171] According to some embodiments, the organic solvent comprises an ether selected from the group consisting of: diethyl ether, methyl ethyl ether, ethyl propyl ether, methyl propyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran and a combination thereof.

[00172] According to some embodiments, the organic solvent comprises a ketone selected from the group consisting of: acetone, ethyl methyl ketone, diethyl ketone and a combination thereof.

[00173] According to some embodiments, the organic solvent comprises a sulfoxide or a sulfone selected from the group consisting of: dimethyl sulfoxide, dimethyl sulfone, sulfolane and a combination thereof.

[00174] According to some embodiments, the organic solvent comprises an amide selected from the group consisting of: dimethyl formamide, dimethyl acetamide, acetamide, N-methylpyrrolidone and a combination thereof.

[00175] According to some embodiments, the organic solvent comprises a nitrile selected from the group consisting of: acetonitrile, propionitrile and a combination thereof.

[00176] According to some embodiments, the organic solvent comprises an ester or al aldehyde selected from the group consisting of: methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methyl formate, ethyl formate, ethyl propionate, methyl propionate and a combination thereof.

[00177] According to some embodiments, the organic solvent comprises a haloalkane selected from the group consisting of: chloroform, dichloromethane and a combination thereof. It is to be understood that the term "haloalkane", as used herein, refers to either mono-halogenated or poly -halogenated species. [00178] According to some embodiments, the organic solvent comprises an aromatic hydrocarbon or a halogenated aromatic cycle, selected from the group consisting of: chlorobenzene, toluene, benzene, xylene and a combination thereof.

[00179] According to some embodiments, the organic solvent comprises an alkane selected from the group consisting of: hexane, hexanes, petroleum ether, pentane, pentanes, heptane, octane, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane and a combination thereof.

[00180] According to some embodiments, the organic solvent is a polar organic solvent.

[00181] The term "polar solvent" as used herein means a solvent that tends to interact with other compounds or itself through acid-base interactions, hydrogen bonding, dipole- dipole interactions, or by dipole-induced dipole interactions.

[00182] According to some embodiments, the polar organic solvent is selected from the group consisting of: ethanol, n-propanol, isopropanol, 1 -butanol, 2-butanol, secbutanol, t-butanol, 1 -pentanol, 2-pentanol, 3 -pentanol, neopentanol, 3 -methyl- 1- butanol, 2-methyl-l -butanol, 3-methyl-2 -butanol, 2-methyl-2-butanol, ethylene glycol, ethylene glycol monomethyl ether, diethyl ether, methyl ethyl ether, ethyl propyl ether, methyl propyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, acetone, ethyl methyl ketone, diethyl ketone, dimethyl sulfoxide, dimethyl sulfone, sulfolane, dimethyl formamide, dimethyl acetamide, acetamide, N-methylpyrrolidone, acetonitrile, propionitrile, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methyl formate, ethyl formate, ethyl propionate, methyl propionate, chloroform, dichloromethane, tetrachloroethylene and combinations thereof. Each possibility represents a separate embodiment of the present invention. According to some embodiments, the polar organic solvent is an alcohol, an ether, an ester, an amide, an aldehyde, a sulfoxide, a sulfone, a ketone, a nitrile, and combinations thereof. Optional alcohols, ethers, esters, amides, aldehydes, sulfoxides, sulfones, ketones and nitriles are specified above.

[00183] According to some embodiments, the organic solvent is a non-polar organic solvent.

[00184] The term "non-polar solvent" as used herein means a solvent that is not a polar solvent. Non-polar solvents interact with other compounds or themselves predominantly through dispersion forces. Non-polar solvents interact with polar solvents mainly through dipole-induced dipole interactions or through dispersion forces.

[00185] Non-polar organic solvents suitable for use in the invention may be selected from acyclic or cyclic, saturated or unsaturated aliphatic hydrocarbons and aromatic hydrocarbons, each of which is optionally substituted by one or more halogens, and combinations thereof. In particular embodiments, the non-polar organic solvent is selected from C5-C10 alkanes, C5-C10 cycloalkanes, Ce-Cu aromatic hydrocarbons and combinations thereof. According to some embodiments, the C5-C10 alkane is selected from the group consisting of pentane, hexane, heptane, octane, nonane, decane, cyclohexane, and isomers and mixtures thereof. According to some embodiments, the non-polar organic solvent is selected from the group consisting of: chlorobenzene, toluene, benzene, xylene, hexane, hexanes, petroleum ether, pentane, pentanes, heptane, octane, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane and combinations thereof. Each possibility represents a separate embodiment of the present invention.

[00186] According to some embodiments, the non-aqueous solvent is a non-organic solvent.

[00187] According to some embodiments, the non-aqueous solvent is selected from the group consisting of liquid CO2, supercritical CO2 and a perfuoroalkane. According to some embodiments, the non-aqueous solvent is selected from the group consisting of liquid CO2 and supercritical CO2.

[00188] According to some embodiments, the organic solvent is selected from the group consisting of: ethanol, n-propanol, isopropanol, 1 -butanol, 2-butanol, secbutanol, t-butanol, 1 -pentanol, 2-pentanol, 3 -pentanol, neopentanol, 3 -methyl- 1- butanol, 2-methyl-l -butanol, 3-methyl-2 -butanol, 2-methyl-2-butanol, ethylene glycol, ethylene glycol monomethyl ether, diethyl ether, methyl ethyl ether, ethyl propyl ether, methyl propyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, acetone, ethyl methyl ketone, diethyl ketone, dimethyl sulfoxide, dimethyl sulfone, sulfolane, dimethyl formamide, dimethyl acetamide, acetamide, N-methylpyrrolidone, acetonitrile, propionitrile, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methyl formate, ethyl formate, ethyl propionate, methyl propionate, chloroform, dichloromethane, tetrachloroethylene, chlorobenzene, toluene, benzene, xylene, hexane, hexanes, petroleum ether, pentane, pentanes, heptane, octane, heptanes, octanes, nonanes, decanes, cyclopentane, cyclohexane, cycloheptane, liquid CO2, supercritical CO2 and a perfuoroalkane and combinations thereof. Each possibility represents a separate embodiment of the present invention. According to some embodiments, the organic solvent is selected from the group consisting of: ethanol, n-propanol, isopropanol, 1 -butanol, 2-butanol, sec -butanol, t- butanol, 1 -pentanol, 2-pentanol, 3 -pentanol, neopentanol, 3 -methyl- 1 -butanol, 2- methyl-1 -butanol, 3-methyl-2-butanol, 2-methyl-2-butanol, ethylene glycol, ethylene glycol monomethyl ether, diethyl ether, methyl ethyl ether, ethyl propyl ether, methyl propyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, dihydrofuran, furan, pyran, dihydropyran, tetrahydropyran, acetone, ethyl methyl ketone, diethyl ketone, dimethyl sulfoxide, dimethyl sulfone, sulfolane, dimethyl formamide, dimethyl acetamide, acetamide, N-methylpyrrolidone, acetonitrile, propionitrile, methyl acetate, ethyl acetate, propyl acetate, acetaldehyde, methyl formate, ethyl formate, ethyl propionate, methyl propionate, chloroform, dichloromethane, tetrachloroethylene, chlorobenzene, toluene, benzene, xylene, liquid CO2, supercritical CO2 and a perfuoroalkane and combinations thereof. Each possibility represents a separate embodiment of the present invention.

[00189] Thus, according to some embodiments, the non-aqueous solvent of step (a) is selected from the group consisting of supercritical CO2, liquid CO2, an alcohol, an ester, a ketone, an ether, an alkane, a haloalkane and combinations thereof. According to some embodiments, the non-aqueous solvent of step (a) is selected from the group consisting of supercritical CO2, liquid CO2, an alcohol, an ester, a ketone, an ether, an alkane, a haloalkane and combinations thereof. According to some embodiments, the non-aqueous solvent is selected from the group consisting of supercritical CO2, liquid CO2, ethanol, n-propanol isopropanol, ethyl acetate, acetone, diethyl ether, tetrahydrofuran, methyl tert-butyl ether, pentane, hexane, heptane, dichloromethane, chloroform and combinations thereof.

[00190] According to some embodiments, the non-aqueous solvent is selected from the group consisting of ethanol, acetone, hexane and combinations thereof. According to some embodiments, the non-aqueous solvent is ethanol. According to some embodiments, the non-aqueous solvent is hexane. According to some embodiments, the non-aqueous solvent is acetone.

[00191] According to some embodiments, the at least one cannabinoid acid is extracted from a plant material, wherein the plant is of cannabis genus. According to some embodiments, the plant material is selected from Cannabis Indica, Cannabis Sativa and cannabis species engineered to have high THC/THCA content. According to some embodiments, the cannabis strain is a THCA enriched strain. According to some embodiments, the cannabis plant material comprises a THCA-enriched cannabis strain.

[00192] According to some embodiments, the at least one cannabinoid acid comprises tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), salts thereof or a combination thereof. According to some embodiments, the at least one cannabinoid acid or salt thereof comprises THCA or a salt thereof.

[00193] According to some embodiments, the aqueous base comprises sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate or a combination thereof. Each possibility represents a separate embodiment. According to some embodiments, the aqueous base is selected from the group consisting of aqueous sodium hydroxide, aqueous potassium hydroxide, aqueous lithium hydroxide, aqueous magnesium hydroxide, aqueous sodium carbonate and aqueous potassium. According to some embodiments, the aqueous base comprises sodium hydroxide. According to some embodiments, wherein the aqueous base of step (a) comprises sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate or a combination thereof.

[00194] According to some embodiments, the aqueous base is aqueous sodium hydroxide. According to some embodiments, the aqueous base is aqueous sodium hydroxide at a concentration in the range of 0.01M to IM.

[00195] According to some embodiments, the aqueous base comprises a hydroxide anion at a concentration in the range of 0.01M to 0.5M. According to some embodiments, the aqueous base comprises a hydroxide anion at a concentration in the range of 0.05M to 0.5M. According to some embodiments, the aqueous base comprises a hydroxide anion at a concentration in the range of 0.1M to 0.25M [00196] According to some embodiments, the process further comprises a step of grinding the cannabis plant material prior to step (a).

[00197] According to some embodiments, the contacting of step (a) is maintained for at least 1 hour. According to some embodiments, the contacting of step (a) is maintained for at least 2 hours. According to some embodiments, the contacting of step (a) is maintained for at least 4 hours. According to some embodiments, the contacting of step (a) is maintained for at least 6 hours. According to some embodiments, the contacting of step (a) is maintained for at least 8 hours. According to some embodiments, the contacting of step (a) is maintained for at least 10 hours. According to some embodiments, the contacting of step (a) is maintained for at least 12 hours. According to some embodiments, the contacting of step (a) is maintained for at least 15 hours. According to some embodiments, the contacting of step (a) is maintained for at least 18 hours. According to some embodiments, the contacting of step (a) is maintained for at least 21 hours. According to some embodiments, the contacting of step (a) is maintained for at least 24 hours.

[00198] According to some embodiments, there is provided stable aqueous cannabinoid composition, prepared by the process of the present invention. According to some embodiments, the stable aqueous cannabinoid composition disclosed herein is prepared by the process of the present invention.

Method, uses, means and devices for administration via inhalation

[00199] According to some embodiments, the stable cannabinoid composition is formulated for administration via inhalation. According to some embodiments, the stable cannabinoid composition is for administration via inhalation. According to some embodiments, the stable cannabinoid composition is for use via inhalation.

[00200] According to some embodiments, the present stable aqueous cannabinoid composition is suitable for use in the administration of a cannabinoid via inhalation

[00201] The phrases "suitable for use in the administration via inhalation", "suitable for administration via inhalation" and "suitable for inhalation" are interchangeable and refer to compositions, that may be administered to a human subject without the subject experiencing undue toxicity and the like, and effective for the intended use of the administration (e.g. therapeutic or recreational). For example, several extraction processes of cannabis products leave remainders of organic solvents and/or other chemical, which are hazardous to the human health and are present in the extracted composition. Such not purified compositions are examples of compositions, which are not suitable for administration via inhalation. According to some embodiments, the cannabinoid composition is formulated for inhalation. According to some embodiments, the present stable aqueous cannabinoid composition is for use in the administration of a cannabinoid via inhalation

[00202] According to some embodiments, the composition is provided in a kit, wherein the kit comprises the stable aqueous cannabinoid composition of the present invention and further comprises instructions for use via inhalation.

[00203] According to some embodiments, the at least one cannabinoid acid is the sole active ingredient in the stable aqueous cannabinoid composition. According to some embodiments, the composition comprises cannabinoid(s) as the only active ingredient.

[00204] The term "active ingredient" refers to an agent, active ingredient compound or other substance, or compositions and mixture thereof that provide some pharmacological and/or biological, often beneficial, effect.

[00205] According to some embodiments, the stable aqueous cannabinoid composition is a stable aqueous pharmaceutical composition.

[00206] According to some embodiments, the present stable aqueous cannabinoid composition is for use for the treatment of a medical condition. According to some embodiments, the present pharmaceutical composition is for use for the treatment of a medical condition. According to some embodiments, the present use via inhalation is for the treatment of a medical condition.

[00207] According to some embodiments, there is provided a method of treating medical condition, the method comprises administering the stable aqueous cannabinoid composition of the present invention to a subject in need thereof. According to some embodiments, there is provided a method of treating medical condition, the method comprises administering the stable aqueous pharmaceutical composition of the present invention to a subject in need thereof. According to some embodiments, the administration is via inhalation. [00208] According to some embodiments, the use is for the treatment of a disease, disorder or symptom amenable to treatment with THC.

[00209] According to some embodiments, the disease, disorder or symptom amenable to treatment with THC is selected from the group consisting of pain, impaired neurological function, inflammation, nausea, vomiting, convulsions, low appetite and glaucoma.

[00210] According to some embodiments, the stable aqueous cannabinoid composition may comprise one or more active agents, other than cannabinoid(s). According to some embodiments, the one or more active agents include one or more pharmaceutically active agents. According to some embodiments, the one or more active agents are suitable or may be adjusted for inhalation. According to some embodiments, the one or more pharmaceutically active agents are directed for treatment of a medical condition through inhalation.

[00211] According to some embodiments, the administration of the cannabinoid acid or salt thereof via inhalation comprises generating an inhalable aerosol upon heating the at least one cannabinoid acid or salt thereof. According to some embodiments, the administration of the cannabinoid acid or salt thereof via inhalation comprises generating an inhalable aerosol upon heating the at least one cannabinoid acid or salt thereof with an electronic vaporizer.

[00212] According to some embodiments, there is provided a vaporization filling composition comprising the cannabinoid composition as described herein.

[00213] According to some embodiments, the vaporization filling composition is selected from an electronic cigarette cartridge filling composition and a vaporizer cartridge filling composition.

[00214] According to some embodiments, there is provided an electronic vaporizer cartridge comprising a liquid container, wherein the liquid container contains the stable aqueous cannabinoid composition of the present intention.

[00215] According to some embodiments, there is provided a method of delivering a cannabinoid to a user of an electronic vaporizer via inhalation, the method comprising the steps of: (i) providing the stable aqueous cannabinoid composition of any one of the present invention; and

(ii) aerosolizing the stable aqueous cannabinoid composition of step (i) with an electronic vaporizer, to form an inhalable aerosol, wherein the inhalable aerosol is inhaled by the user of the electronic vaporizer.

[00216] According to some embodiments, there is provided a method of delivering a cannabinoid to a user of an electronic vaporizer via inhalation, the method comprising the steps of:

(i) providing a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5; and

[00217] According to some embodiments, the method of delivering a cannabinoid to a user of an electronic vaporizer via inhalation is for non-medical purposes.

[00218] According to some embodiments, there is provided a method of treating a medical condition amenable to treatment with THC, the method comprising the steps of:

(i) providing a cannabinoid composition as disclosed herein;

(ii) aerosolizing the cannabinoid composition of step (i) with an aerosol generating device; and

(iii) delivering the inhalable aerosol of step (ii) to a subject in need thereof, thereby treating the medical condition amenable to treatment with THC.

[00219] According to some embodiments, there is provided a method of treating a medical condition amenable to treatment with THC, the method comprising the steps of: (i) providing a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5;

[00220] According to some embodiments, the aerosolizing of step (ii) comprises heating the stable aqueous cannabinoid composition of step (i) with an electronic vaporizer.

[00221] According to some embodiments, the aerosol generating device is selected from the group consisting of an electronic vaporizer, a nebulizer and an inhaler. According to some embodiments, the aerosol generating device is an electronic vaporizer. According to some embodiments, the aerosol generating device is a nebulizer. According to some embodiments, the aerosol generating device is an inhaler. According to some embodiments, the aerosol generating device is an inhaler or a nebulizer.

[00222] According to some embodiments, the electronic vaporizer is a vaping device or an electronic cigarette. According to some embodiments, the electronic vaporizer is a vaping device. According to some embodiments, the electronic vaporizer is an electronic cigarette.

[00223] The term "aerosol generating device" refer to a device configured to produce a vapor or aerosol from a liquid or solid composition, aerosol generating devices are typically used to deliver a solid or liquid (including semi liquid) composition to a subject in need thereof in an inhalable form (i.e., in a substantially gaseous form). Aerosol generating devices include nebulizers and inhalers, which typically produce aerosols by application of mechanical force on the compositions (e.g., by gas flow or vacuum), and to vaporizers and electronic cigarettes, which typically heating unit(s) and produce aerosols by vaporizing the composition. In both instances, the composition is delivered through an outlet, wherein in the latter instances (i.e., vaporizers and electronic cigarettes) the vapor is usually at least partially being condensed to form droplets of the composition, through the delivery.

[00224] The present composition is typically aerosolized by aerosol generating devices, which include heating units, and are typically conventionally referred to as vaporizers. Specifically, the typical convention is that aerosol generating devices for aerosolizing nicotine/ tobacco compositions are called electronic cigarettes, whereas devices for aerosolizing cannabinoid/cannabis compositions are called vaporizer or v aping devices.

[00225] As used herein the term "electronic vaporizer" refers either to electronic cigarettes or to vaporizer and vaping devices.

[00226] According to some embodiments, the inhalable aerosol is inhaled by the user of the electronic vaporizer. According to some embodiments, the inhalable aerosol is inhaled by the subject. According to some embodiments, the method further comprises the step of inhaling the inhalable aerosol by a user. According to some embodiments, the method further comprises the step of inhaling the inhalable aerosol by the subject. According to some embodiments, the method further comprises the step of inhaling the inhalable aerosol by a user of an electronic vaporizer.

[00227] According to some embodiments, the delivering of the cannabinoid acid or salt thereof to a user comprises delivering of the cannabinoid formed by the acid decarboxylation to a user comprises delivering the cannabinoid to the respiratory system of the user. According to some embodiments, the delivering of the cannabinoid acid to the subject comprises delivering of a cannabinoid formed by the acid decarboxylation to the respiratory system of the subject.

[00228] It is to be understood that the embodiments related to stable aqueous cannabinoid composition and/or the pharmaceutical composition above, may apply for any of the methods and uses disclosed herein. Specifically, wherein the method or use is for treatment of a subject, the stable aqueous cannabinoid composition may be a pharmaceutical composition, according to some embodiments.

[00229] As detailed herein the present composition may be used for administration of the cannabinoid via inhalation to a subject. According to some embodiments, the administration of the cannabinoid via inhalation comprises generating an inhalable aerosol from the stable aqueous cannabinoid composition. According to some embodiments, the administration of the cannabinoid via inhalation comprises generating an inhalable aerosol from the cannabinoid composition upon heating the stable aqueous cannabinoid composition in an aerosol generating device. According to some embodiments, the administration of the cannabinoid via inhalation comprises generating an inhalable aerosol from the stable aqueous cannabinoid composition upon heating the cannabinoid composition in an electronic vaporizer. According to some embodiments, the administration of the cannabinoid via inhalation comprises generating an inhalable aerosol upon heating the stable aqueous cannabinoid composition in an electronic vaporizer.

[00230] Surprisingly, it was found that the basic composition (pH of at least 8.5 or at least 9, or at least 10) is suitable for delivery to electronic vaporizer users. Specifically, although such basic compositions are not suitable for direct use of human, it was found that upon aerosolization, a substantially pH neutral aerosol formed, which is compatible with inhalation. Without wishing to be bound by any theory of mechanism of action, the basic cannabinoid composition comprises non-volatile bases, which are not aerosolized, and organic material, comprising THCA, present mainly as a basic salt, e.g., THCA-sodium salt. Upon heating and aerosolization with the electronic vaporizer, THCA-sodium salt, which is in equilibrium with THCA, undergoes decarboxylation to form THC, which is aerosolized together with the water medium. THC is pH neutral, therefore, the aerosol is substantially neutral and suitable for the use of human subjects.

[00231] According to some embodiments, the inhalable aerosol formed in step (ii) has a pH in the range of 5.5 to 7.5.

[00232] According to some embodiments, the inhalable aerosol has a pH in the range of 5.5 to 8.5. According to some embodiments, the inhalable aerosol has a pH in the range of 6.0 to 7.5. According to some embodiments, the inhalable aerosol has a pH in the range of 6.5 to 7.5. According to some embodiments, the inhalable aerosol has a pH in the range of 5.5 to 7.5.

[00233] Another requirement from the generated aerosol is to have droplets having the required size so as to reach the lungs of the electronic vaporizer user. These requirements are detailed below. According to some embodiments, the aerosol has droplets having a mass median aerodynamic diameter (MMAD) of at most 5 microns. [00234] As elaborated above, the pH of the stable aqueous cannabinoid composition is highly basic, whereas the pH of the aerosol produced therefrom is typically substantially neutral, according to some embodiments. This may be the result of the formation of the neutral compound THC from THCA basic salt.

[00235] According to some embodiments, the aerosolizing of step (ii) comprises heating the stable aqueous cannabinoid composition of step (i) with the electronic vaporizer. According to some embodiments, the aerosolizing of step (ii) comprises heating the stable aqueous cannabinoid composition of step (i) with the aerosol generating device.

[00236] As detailed above, the methods of the current invention are effective in delivering THC to the respiratory system of the electronic vaporizer user and/or to the respiratory system of the subject in need of treatment with said cannabinoid, according to some embodiments.

[00237] As used herein, "respiratory system" refers to the system of organs in the body responsible for the intake of oxygen and the expiration of carbon dioxide. The system generally includes all the air passages from the nose to the pulmonary alveoli. In mammals it is generally considered to include the lungs, bronchi, bronchioles, trachea, nasal passages, and diaphragm. For purposes of the present disclosure, delivery of a drug to the "respiratory system" indicates that a drug is delivered to one or more of the air passages of the respiratory system, in particular to the lungs.

[00238] The correlation between droplet size and deposition thereof in the respiratory tract has been established. Droplets around 10 micron in diameter are suitable for deposition in the oropharynx and the nasal area; droplets below around 4 micron in diameter are suitable for deposition in the central airways and may be especially beneficial for delivery of cannabinoid the subjects in a need thereof. The droplets formed by aerosolizing the cannabinoid composition of the current invention are small, having droplet size in the range of 0.1 to 5 micron, according to some embodiments.

[00239] According to some embodiments, there is provided an electronic vaporizer cartridge comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition as disclosed herein. According to some embodiments, there is provided an electronic vaporizer cartridge comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5. According to some embodiments, there is provided an electronic cigarette comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition as disclosed herein. According to some embodiments, there is provided an electronic vaporizer comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5.

[00240] According to some embodiments, there is provided an aerosol generating device cartridge comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition as disclosed herein. According to some embodiments, there is provided an aerosol generating device cartridge comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5. According to some embodiments, there is provided an aerosol generating device comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition as disclosed herein. According to some embodiments, there is provided an aerosol generating device comprising a liquid container, wherein the liquid container contains a stable aqueous cannabinoid composition comprising more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5.

[00241] It is to be understood that embodiments referring to the stable aqueous cannabinoid compositions presented herein also apply to the cannabinoid compositions contained in any one of the electronic vaporizer, electronic vaporizer cartridge, aerosol generating device and/or aerosol generating device cartridge disclosed herein. Specifically, an electronic vaporizer is an aerosol generating device, which comprises a heating unit assisting in the production of the aerosol. Aerosol compositions

[00242] According to some embodiments, there is provided an aerosol composition comprising tetrahydrocannabinol (THC) at a total weight of at least 10% w/w based on the total weight of the aerosol composition, and water 60-90% w/w based on the total weight of the aerosol composition, wherein the aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of at most 5 microns.

[00243] As used herein the term "aerosol" refers to a suspension of solid or liquid particles in a gas. As used herein "aerosol" may be used generally to refer to a drug that has been vaporized, nebulized, or otherwise converted from a solid or liquid form to an inhalable form including suspended solid or liquid drug particles. According to some embodiments, the drug particles include THC particles.

[00244] According to some embodiments, the aerosol is prepared by aerosolizing the stable aqueous cannabinoid composition of the present invention.

[00245] According to some embodiments, aerosol composition comprises 60-85% water w/w based on the total weight of the aerosol composition. According to some embodiments, aerosol composition comprises 60-80% water w/w based on the total weight of the aerosol composition. According to some embodiments, aerosol composition comprises 65-85% water w/w based on the total weight of the aerosol composition. According to some embodiments, aerosol composition comprises 65-85% water w/w based on the total weight of the aerosol composition.

[00246] According to some embodiments, the aerosol has a pH in the range of 5.5 to 7.5.

[00247] According to some embodiments, the aerosol composition is having a pH in the range of 5.5 to 7.5. Specifically, upon collection of the aerosol, the pH was measured to be substantially neutral, indicating the substantial disappearance of THCA and formation of the pH neutral THC.

[00248] According to some embodiments, the aerosol further comprises tetrahydrocannabinolic acid (THCA).

[00249] Without wishing to be bound by any theory of mechanism of action, the aerosol of the current invention comprises THCA as a main component, and upon aerosolization, it undergoes decarboxylation, to form an aerosol comprising mainly THC. However, according to some embodiments, traces of THCA may still be present in the aerosol.

[00250] According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 5 microns. According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 4 microns. According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 3 microns. According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 2 microns. According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 1 micron. According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 0.8 microns. According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 0.6 microns. According to some embodiments, the aerosol composition comprises droplets having a mass median aerodynamic diameter (MMAD) of at most 0.5 microns.

[00251] It was surprisingly found that aerosolization of a formulation as disclosed herein, results in droplets having a mass median aerodynamic diameter (MMAD) sufficiently small so as to reach the lungs, rather than precipitate on their way thereto. The small droplets reaching the lungs enable efficient respiratory delivery of the cannabinoid(s). This is an overall advantage as maximizing the delivery of cannabinoid(s) to the lungs, while minimizing its deposition in the mouth and throat are considered highly beneficial.

[00252] The terms 'droplet size' and 'mass median aerodynamic diameter', also known as MMAD, as used herein are interchangeable. MMAD is commonly considered as the median particle diameter by mass. MMAD may be evaluated by plotting droplet size vs. the cumulative mass fraction (%) in the aerosol. MMAD may then be determined according to the interpolated droplet size corresponding to the point, where the cumulative mass fraction is 50%. This point represents the estimated values of particle sizes, above which the droplets are responsible to half to masses and below which the droplets are responsible to the other halves, in each solution.

[00253] According to some embodiments, the aerosol comprises droplets having a Geometric Standard Diameter (GSD) within the range of about 0.2-7 micron. According to some embodiments, the aerosol comprises droplets having a GSD within the range of about 0.2-5 micron.

[00254] According to some embodiments, the aerosol composition further comprises an additive selected from the group consisting of a carrier, a preservative, an anticoughing agent, a propellant and a flavorant.

[00255] According to some embodiments, the aerosol comprises a viscosity enhancing agent. According to some embodiments, the aerosol comprises glycerol. According to some embodiments, viscosity enhancing agent comprises glycerol.

[00256] According to some embodiments, the aerosol further comprises a surfactant as disclosed herein with respect to the stable aqueous cannabinoid composition. According to some embodiments, the aerosol further comprises a non-ionic surfactant as disclosed herein with respect to the stable aqueous cannabinoid composition. According to some embodiments, the aerosol further comprises polysorbate.

[00257] According to some embodiments, the aerosol composition further comprises at least one carrier acceptable for inhalation. According to some embodiments, the carrier is stable under basic pH conditions. According to some embodiments, the carrier is water soluble under basic pH conditions. According to some embodiments, the aerosol composition further comprises at least one pharmaceutically acceptable carrier, which is acceptable for inhalation. According to some embodiments, the pharmaceutically acceptable carrier is stable under basic pH conditions. According to some embodiments, the pharmaceutically acceptable carrier is water soluble under basic pH conditions. According to some embodiments, the aerosol composition further comprises at least one stabilizer. According to some embodiments, the stabilizer is stable under basic pH conditions. According to some embodiments, the stabilizer is water soluble under basic pH conditions. According to some embodiments, the aerosol composition further comprises at least one additive selected from the group consisting of a propellant, an anti-coughing agent and a flavorant. According to some embodiments, the aerosol composition further comprises at least one additive selected from the group consisting of, an anti-coughing agent and a flavorant. According to some embodiments, the aerosol composition further comprises at least one anti-coughing agent. According to some embodiments, the aerosol composition further comprises at least one flavorant. According to some embodiments, the aerosol composition further comprises at least one additive at a concentration of 0.1-1% w/w. According to some embodiments, the aerosol composition further comprises at least one additive at a concentration of 0.1-0.5% w/w. According to some embodiments, the aerosol composition further comprises at least one additive at a concentration of 0.1-0.3% w/w. According to some embodiments, the additive is approved for use in inhaling composition. According to some embodiments, the additive is stable at basic aqueous conditions. According to some embodiments, the additive is soluble at basic aqueous conditions. According to some embodiments, the flavorant is a sweetener. According to some embodiments, the sweetener is selected from the group of artificial sweeteners including saccharine, aspartame, dextrose and fructose. According to some embodiments, the aerosol composition further comprises at least one preservative. According to some embodiments, the preservative is selected from the group consisting of benzyl alcohol, propylparaben, methylparaben, benzalkonium chloride, phenylethyl alcohol, chlorobutanol, potassium sorbate, phenol, m-cresol, o-cresol, p- cresol, chlorocresol and combinations thereof. According to some embodiments, the at least one anti-coughing agent is selected from expectorants, antitussives or both. According to some embodiments, the at least one anti-coughing agent is selected from the group consisting of menthol, dextromethorphan, dextromethorphan hydrobromide, hydrocodone, caramiphen dextrorphan, 3 -methoxy morphinan or morphinan- 3-ol, carbetapentane, codeine, acetylcysteine and combinations thereof.

[00258] According to some embodiments, the additive is selected from menthol, eucalyptol, tyloxapol and a combination thereof. According to some embodiments, the additive is selected from menthol, eucalyptol, tyloxapol and a combination thereof, and is present at a concentration of 0.1-0.5% w/w based on the total weight of the cannabinoid composition.

[00259] According to some embodiments, the aerosol composition is prepared by aerosolizing a cannabinoid composition as disclosed herein. [00260] Certain embodiments of the present disclosure may include some, all, or none of the above advantages. One or more technical advantages may be readily apparent to those skilled in the art from the figures, descriptions and claims included herein. Moreover, while specific advantages have been enumerated above, various embodiments may include all, some or none of the enumerated advantages.

[00261] In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the figures and by study of the following detailed descriptions.

EXAMPLES

Example 1: Preparation of a stable concentrated aqueous cannabinoid formulation for inhalation

[00262] The formulation for inhalation analyzed in the experiments below included a stable aqueous composition of tetrahydrocannabinolic acid (THCA). The stable aqueous composition was prepared by grinding a 1.8 gr sample of THCA-enriched cannabis strain and placing the ground plant material in a glass vessel. About 0.1 liters of ethanol was added to the glass vessel and the mixture was stirred/left over night. All the material was then transferred from the glass vessel to a stainless-steel mesh and the plant material was macerated by application of physical pressure. The liquid contents were then centrifuged and a clear ethanol solution was separated from the solids and collected. The solution was visibly clear. The solution was heated gently to evaporate off ethanol until concentrated to 10 ml. The solution was measured by HPLC to contain about 37.87 mg/ml THCA.

[00263] One milliliter (1 ml) of 0.1M NaOH and 0.5% w/w polysorbate 80 were added to the dried extract and the mixture was agitated. To the basic composition, 20 microliters of 4M NaOH was added to obtain a pH value of between 11-12. The liquid composition was centrifuged and the supernatant liquid was collected. The composition was left to stand for a few hours, surprisingly resulting in phase separation into two aqueous layers. The top phase contained 1.5% THCA and had a pH value of around 12. The bottom phase contained 16.4% THCA and had a pH value of around 12.

[00264] The phases were separated and the concentrated bottom phase was examined. The bottom phase was viscous compared to the parent basic solutions, and was measured by HPLC to have 16.4% THCA w/w. Moreover, despite the high THCA load, it was found that the composition is stable for at least one week, wherein during this period the THCA concentration remains substantially unaffected. The concentrated composition was ready and suitable for inhalation using an electronic vaporizer.

[00265] The formulation was aerosolized from a standard electronic vaporizer. The aerosol was collected and its pH was measured to be substantially neutral, indicating that the THCA underwent decarboxylation to form the pH neutral compound THC in the aerosol.

Example 2: Preparation of a stable concentrated aqueous cannabinoid formulation for inhalation

[00266] A dried THCA extract was prepared as described in Example 1. The dried extract was added 0. IM NaOH and 0.5% w/w polysorbate 80. The aqueous 0. IM NaOH solution was added until the pH value reached between 11-12. An aqueous 0.2M NaCl solution was added until phase separation into two aqueous layers resulted. The top phase contained less than 10% THCA, it was not viscous, and it had a pH value of around 11-12. The bottom phase contained more than 15% THCA, it was viscous, and had a pH value of around 11-12.

[00267] The phases were separated and the concentrated bottom phase was examined. The bottom phase was viscous compared to the parent basic solutions, and was measured by HPLC to have over 15% THCA w/w. Moreover, despite the high THCA load, it was found that the composition is stable for at least one week, wherein during this period the THCA concentration remains substantially unaffected. The concentrated composition was ready and suitable for inhalation using an electronic vaporizer.

[00268] The formulation was aerosolized from a standard electronic vaporizer. The aerosol was collected and its pH was measured to be substantially neutral, indicating that the THCA underwent decarboxylation to form the pH neutral compound THC in the aerosol.

[00269] Although the invention is described in conjunction with specific embodiments thereof, it is evident that numerous alternatives, modifications and variations that are apparent to those skilled in the art may exist. It is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth herein. Other embodiments may be practiced, and an embodiment may be carried out in various ways. Accordingly, the invention embraces all such alternatives, modifications and variations that fall within the scope of the appended claims.

Claims

57

1. A stable aqueous cannabinoid composition comprising at least 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, wherein the cannabinoid composition has a pH of at least 8.5.

2. The stable aqueous cannabinoid composition of claim 1, which is in a form selected from the group consisting of: a solution, a suspension, a gel and an emulsion.

3. The stable aqueous cannabinoid composition of claim 2, which is in a form selected from the group consisting of: a gel, a micro-emulsion, nano-emulsion and a colloidal suspension of micro-colloids or nano-colloids.

4. The stable aqueous cannabinoid composition of any one of claims 1-3, which has an ionic strength in the range of 0.3 M to 2M.

5. The stable aqueous cannabinoid composition of any one of claims 1-4, which has a pH in the range of 10 to 12.

6. The stable aqueous cannabinoid composition of any one of claims 1-5, comprising at least 15% w/w of the at least one cannabinoid acid or salt thereof.

7. The stable aqueous cannabinoid composition of any one of claims 1-6, wherein the non-ionic surfactant comprises a polysorbate.

8. The stable aqueous cannabinoid composition of claim 7, wherein the polysorbate is polysorbate 80.

9. The stable aqueous cannabinoid composition of any one of claims 1-8, comprising 0.02% w/w to 0.06% w/w polysorbate 80 non-ionic surfactant.

10. The stable aqueous cannabinoid composition of any one of claims 1-9, having viscosity in the range of 1.25 to 50 mPa- s at 20°C.

11. The stable aqueous cannabinoid composition of any one of claims 1-10, which further comprises glycerol.

12. The stable aqueous cannabinoid composition of any one of claims 1-11, wherein the at least one cannabinoid acid or salt thereof comprises 58 tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), salts thereof or a combination thereof.

13. The stable aqueous cannabinoid composition of claim 12, wherein the at least one cannabinoid acid or salt thereof comprises THCA or a salt thereof.

14. The stable aqueous cannabinoid composition of any one of claims 1-13, which is substantially devoid of organic solvents.

15. The stable aqueous cannabinoid composition of any one of claims 1-14, which comprises at least 60% w/w water.

16. The stable aqueous cannabinoid composition of any one of claims 1-13, wherein the aqueous composition is prepared by a process comprising the steps of:

(b) adding a salt or an aqueous salt solution to the composition of step (a) until it reaches an ionic strength of at least 0.7M, to form phase separation, between a first phase comprises more than 10% w/w of at least one cannabinoid acid or a salt thereof and a non-ionic surfactant, and a second phase;

(c) separating the first phase from the second phase.

17. The stable aqueous cannabinoid composition of claim 16, wherein the process further comprises extracting a cannabis plant material with a non-aqueous solvent and drying the extract to form the dry cannabis plant extract of step (a).

18. The stable aqueous cannabinoid composition of claim 16 or 17, wherein the aqueous base of step (a) comprises a base selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate or a combination thereof. 59 . The stable aqueous cannabinoid composition of any one of claims 16-18, wherein the cannabis plant material comprises a THCA-enriched cannabis strain. . The stable aqueous cannabinoid composition of any one of claims 1-19, which is stable for at least 1 week, during which concentration of the least one cannabinoid acid or a salt thereof remains above 10% w/w. . The stable aqueous cannabinoid composition of any one of claims 1-20, further comprising at least one additive selected from the group consisting of a propellant, an anti-coughing agent and a flavorant. . The stable aqueous cannabinoid composition of any one of claims 1-21, which is formulated for administration via inhalation. . A process for preparing a stable aqueous cannabinoid composition, comprising the steps of:

(c) separating the first phase from the second phase. . The process of claim 23, wherein the process further comprises extracting a cannabis plant material with a non-aqueous solvent and drying the extract to form the dry cannabis plant extract of step (a). . The process of claim 23 or 24, wherein the aqueous base of step (a) comprises sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate or a combination thereof.. The process of any one of claims 23-25, wherein the cannabis plant material comprises a THCA-enriched cannabis strain. 60

27. A stable aqueous cannabinoid composition, prepared by the process of any one of claims 23-26.

28. A vaporization filling composition comprising the cannabinoid composition of any one of claims 1-22 or 27.

29. The vaporization filling composition of claim 28, selected from an electronic cigarette cartridge filling composition and a vaporizer cartridge filling composition.

30. An electronic vaporizer cartridge comprising a liquid container, wherein the liquid container contains the cannabinoid composition of any one of claims 1- 22, or 27.

31. A method of delivering a cannabinoid to a user of an electronic vaporizer via inhalation, the method comprising the steps of:

(i) providing the stable aqueous cannabinoid composition of any one of claims 1-22, or 27; and

32. The method of claim 31, wherein the inhalable aerosol formed in step (ii) has a pH in the range of 5.5 to 7.5.

33. The method of claim 31 or 32, wherein the aerosolizing of step (ii) comprises heating the stable aqueous cannabinoid composition of step (i) with an electronic vaporizer.

34. An aerosol composition comprising tetrahydrocannabinol (THC) at a total weight of at least 10% w/w based on the total weight of the aerosol composition, and water 60-90% w/w based on the total weight of the aerosol composition, wherein the aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of at most 5 microns.

35. The aerosol composition of claim 34, which is prepared by aerosolizing the stable aqueous cannabinoid composition of any one of claims 1-22 or 27. 61 The aerosol composition of claim 34 or 35, having a pH in the range of 5.5 to 7.5. The aerosol composition of any one of claims 34-36, further comprising tetrahydrocannabinolic acid (THCA).